Biomarin Pharmaceutical (BMRN) Interest Expenses (2009 - 2026)

Biomarin Pharmaceutical has disclosed Interest Expenses across 18 years of filings, most recently posting $15.0 million for Q1 2026.

• Quarterly Interest Expenses rose 422.46% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.0 million (up 91.9% YoY) and the FY2025 annual result came in at $10.9 million, down 13.95% from the prior year.
• Interest Expenses improved to $15.0 million in Q1 2026, from $2.8 million in the prior quarter.
• Over five years, Interest Expenses peaked at $15.0 million in Q1 2026 and troughed at $2.6 million in Q4 2024.
• A 5-year average of $4.2 million and a median of $3.6 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses tumbled 57.74% — and 2026, when it soared 422.46%.
• Tracing BMRN's Interest Expenses over 5 years: stood at $3.6 million in 2022, then surged by 68.17% to $6.1 million in 2023, then slumped by 57.74% to $2.6 million in 2024, then increased by 7.8% to $2.8 million in 2025, then soared by 438.44% to $15.0 million in 2026.
• Business Quant data shows BMRN's Interest Expenses at $15.0 million in Q1 2026, $2.8 million in Q4 2025, and $2.6 million in Q3 2025.